153 related articles for article (PubMed ID: 11398880)
21. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.
Fedyanin M; Tryakin A; Bulanov A; Vybarava A; Tjulandina A; Chekini D; Sekhina O; Figurin K; Garin A; Tjulandin S
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1259-64. PubMed ID: 25586890
[TBL] [Abstract][Full Text] [Related]
23. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
Culine S; Theodore C; Court BH; Perrin JL; Droz JP
Br J Urol; 1997 Feb; 79(2):258-62. PubMed ID: 9052479
[TBL] [Abstract][Full Text] [Related]
25. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of advanced testicular cancer and toxicity of chemotherapy].
Kawakita M; Matsuda T; Terachi T; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):783-6. PubMed ID: 10637744
[TBL] [Abstract][Full Text] [Related]
27. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma.
Domont J; Massard C; Patrikidou A; Bossi A; de Crevoisier R; Rose M; Wibault P; Fizazi K
Urol Oncol; 2013 Jul; 31(5):697-705. PubMed ID: 21665493
[TBL] [Abstract][Full Text] [Related]
28. [Testis germ cell tumours: which chemotherapy, for which patients?].
Fléchon A; Droz JP
Ann Urol (Paris); 2007 Apr; 41(2):56-67. PubMed ID: 17486913
[TBL] [Abstract][Full Text] [Related]
29. Stage II Testicular Seminoma: Patterns of Care and Survival by Treatment Strategy.
Glaser SM; Vargo JA; Balasubramani GK; Beriwal S
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):513-21. PubMed ID: 27146264
[TBL] [Abstract][Full Text] [Related]
30. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
[TBL] [Abstract][Full Text] [Related]
31. [Metastatic pure seminomas of the testicle: role of chemotherapy].
Ceccaldi B; Dourthe LM; Houlgatte A; Merrer J
Bull Cancer; 1998 Oct; 85(10):887-91. PubMed ID: 9835865
[TBL] [Abstract][Full Text] [Related]
32. [Low dose COMPE. Cisplatin, vincristine, methotrexate, peplomycin, etoposide chemotherapy for advanced testicular cancer].
Ueda T; Yamauchi T; Kawai T; Ohono Y; Kawakami S; Yonese J
Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):626-31. PubMed ID: 7514699
[TBL] [Abstract][Full Text] [Related]
33. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
34. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
35. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
36. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
39. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
40. Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Deliveliotis C; Thanos A; Klouvas G; Antoniou N; Poulias I; Makatsoris T; Samantas E; Dimopoulos MA
Urology; 2007 Dec; 70(6):1179-83. PubMed ID: 18158042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
